Gain detailed insights into the trading activity of Congress members for Associated Banc on our government trades page. Stay updated on how elected officials are investing in ASB.

Associated Banc - Government Trades

Associated Banc

Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.

News

Downgrades

Financing

Management

Markets

Analyst Ratings

Trading Ideas

BlackRock&#39;s (NYSE: BLK) outlook has been downgraded to negative from stable by Moody&#39;s Investors Service. The action followed the company&#39;s announcement to acquire Preqin for almost $3.2 billion (£2.55 billion) in cash. This marked the second major deal for the company.

BlackRock&#39;s Outlook Lowered by Moody&#39;s on Debt Concern

Real Estate

ZION

Bank OZK&#39;s (NASDAQ: OZK) ratings and outlook have been affirmed by Moody&#39;s Ratings, a division of Moody&#39;s Corporation (NYSE: MCO).

Bank OZK Ratings Affirmed by Moody&#39;s Amid CRE Concerns

Earnings

Zions Bancorporation&#39;s (NASDAQ: ZION) ratings and outlook have been affirmed by Moody&#39;s Ratings, a division of Moody&#39;s Corporation (NYSE: MCO).

Zions&#39; Ratings Reiterated by Moody&#39;s, Outlook Stable

Analyst Color

Price Target

Small Cap

BANC

EWBC

FIBK

PACW

PNFP

Wells Fargo analyst Timur Braziler has assumed coverage of 15 banks in addition to the seven currently covered. The analyst transferred coverage of midcap banks, downgraded 4 to Equal Weight, and became more selective given the risk to earnings (rates, credit) and delayed consolidation benefits, mitigated by inexpensive valuations.

Wells Fargo Analyst Downgrades ASB, BANC, FIBK, FHN Citing Interest Rate Pressures And Credit Risks

red chart shutter3

Large Cap

Mid Cap

Sector ETFs

ETFs

RCBC

STBA

UMBF

S&amp;P Slashes Ratings Of 5 US Regional Banks Facing Growing Challenges

Long Ideas

Insider Trades

Pre-Market Outlook

NWBI

Although US stocks closed mixed on Wednesday, there were a few notable insider trades.

$4.4M Bet On Howard Hughes? Check Out These 3 Stocks Insiders Are Buying

Government

Small Business

General

ABCB

CATY

US Consumer Watchdog Lays Down Rules On Small Business Loan Data

ACHR

BECN

CRNX

ENFN

INTC

NRDY

TCBI

REPX


	Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near highs.
	
	Beneficial owners made some the most notable insider purchases last week.
	
	Some insiders took advantage of public offerings of shares as well.




Last Week&#39;s Notable Insider Buys: Beacon Roofing Supply, Enfusion, Nerdy And More

Penny Stocks

AMEH

ANAB

CSTR

HTLD

IMPL

KNBE

RAIN

RCUS

SWIM

TELL


	Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
	Once again, some insiders took advantage of recent public share offerings to add or bolster stakes.
	Again, biotechnology companies are well represented on this list.




Last Week&#39;s Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More

Intraday Update

Movers

ABEV

ACAM

ACBI

ACCO

ACEL

ACER

ACIW

ACLS

ACRS

ACST

ADOM

AEHR

AGRO

AIMC

AINV

AIRT

ALEX

ALGN

ALGT

ALOT

AMAL

AMKR

AMOT

AMPH

AMRB

AMSC

AMWD

ANIK

ANIX

AOSL

APEN

APLE

APOG

APPN

APYX

AQUA

ARCC

ARCO

ARDC

ARDS

ARKR

AROW

ARPO

ASRV

ATKR

ATRS

AVAL

AVNW

AWSM

AXNX

AZUL

Stocks That Hit 52-Week Lows On Thursday

Associated Banc-Corp

Associated Banc-Corp 6.625% Fixed-Rate Reset Subordinated Notes due 2033

ASSOCIATED BRIT FOOD ORD by Associated British Foods plc

Associated British Foods PLC

ASSOCIATED BRI/F UNSP/ADR by Associated British Foods plc

ASAHI GROUP HLDGS U/ADR by Asahi Group Holdings Ltd.

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Holdings Inc

Aspire Biopharma Holdings, Inc. - Warrant

ASAHI GROUP HOLDINGS ORD by Asahi Group Holdings Ltd.

Asahi Group Holdings Ltd

Associated Banc-Corp Depositary Shares, each representing a 1/40th interest in a share of 5.875% Non-Cumulative Perpetual Preferred Stock, Series E

Associated Banc-Corp Depositary Shares, each representing a 1/40th interest in a share of Associated Banc-Corp 5.625% Non-Cumulative Perpetual Preferred Stock, Series F

9 analysts have shared their evaluations of Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sealed Air, revealing an average target of $40.56, a high estimate of $44.00, and a low estimate of $37.00. Experiencing a 2.12% decline, the current average is now lower than the previous average price target of $41.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1740600048_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Sealed Air among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Stefan Diaz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>George Staphos</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sealed Air. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sealed Air compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sealed Air's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sealed Air's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SEE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sealed Air analyst ratings.</a>
<h2>Get to Know Sealed Air Better</h2>
Sealed Air is organized via two reporting segments. Food care includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Product care includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
<h3>Financial Insights: Sealed Air</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Sealed Air faced challenges, resulting in a decline of approximately -2.66% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Sealed Air's net margin excels beyond industry benchmarks, reaching 6.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 12.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sealed Air's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sealed Air's debt-to-equity ratio stands notably higher than the industry average, reaching 6.01. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sealed Air's Future

Analysts' ratings for PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PROCEPT BioRobotics, presenting an average target of $100.5, a high estimate of $112.00, and a low estimate of $90.00. A 4.29% drop is evident in the current average compared to the previous average price target of $105.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740600041_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive PROCEPT BioRobotics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Nathan Treybeck</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$112.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PROCEPT BioRobotics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for PROCEPT BioRobotics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into PROCEPT BioRobotics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRCT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PROCEPT BioRobotics analyst ratings.</a>
<h2>Discovering PROCEPT BioRobotics: A Closer Look</h2>
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
<h3>Breaking Down PROCEPT BioRobotics's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining PROCEPT BioRobotics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 66.29% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: PROCEPT BioRobotics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -35.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PROCEPT BioRobotics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -8.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PROCEPT BioRobotics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.6%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.33, PROCEPT BioRobotics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRCT

4 Analysts Assess PROCEPT BioRobotics: What You Need To Know

In the last three months, 4 analysts have published ratings on Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $748.5, a high estimate of $785.00, and a low estimate of $714.00. Highlighting a 0.86% decrease, the current average has fallen from the previous average price target of $755.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740600018_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Intuit. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$714.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$730.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$785.00</td>
<td>$765.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$765.00</td>
<td>$765.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Intuit. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Intuit compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Intuit's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Intuit's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INTU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intuit analyst ratings.</a>
<h2>Get to Know Intuit Better</h2>
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
<h3>A Deep Dive into Intuit's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Intuit displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 10.24%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Intuit's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Intuit's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.08%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Intuit's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.6%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intuit's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

4 Analysts Have This To Say About Intuit

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 20 years by 11.37% on an annualized basis producing an average annual return of 19.57%. Currently, Alnylam Pharmaceuticals has a market capitalization of $31.74 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,567.44 today based on a price of $245.20 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740600012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years

Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are trading lower after the company reported fourth-quarter earnings <a href="https://www.benzinga.com//node/43957497">on Tuesday</a> and announced management transitions. 
The Details: Lucid reported a loss of 22 cents per share, beating analysts&#8217; estimate of a loss of 27 cents per share. In addition, the company reported sales of $234.50 million, beating analysts&#8217; estimate of $214.21 million.
Lucid announced it produced 3,386 vehicles in the fourth-quarter and&nbsp;9,029 vehicles throughout the year, in line with its previous&nbsp;guidance&nbsp;of 9,000 vehicles. Furthermore, it delivered 3,099 vehicles throughout the quarter and 10,241 vehicles in 2024, representing 79% increase year-over-year.
Lucid expects production of about 20,00 vehicles throughout 2025.
Additionally, Lucid announced that CEO Peter Rawlinson has stepped down as CEO and will transition to the role of Strategic Technical Advisor to the chairman of the company&#8217;s board.&nbsp;COO Marc Winterhoff has been appointed Interim CEO.
&#8220;2024 was a transformational year for Lucid and I am honored to step into this role as Lucid enters the next phase of its journey,&#8221; said&nbsp;Winterhoff. &#8220;We have an extremely talented team that is laser-focused on ramping production of Lucid Gravity, our technology licensing business, our Midsize platform vehicles, and further monetization opportunities.&#8221;
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>B of A Securities analyst John Murphy downgraded Lucid from a Neutral rating to an Underperform rating and lowered the price target from&nbsp;$3&nbsp;to&nbsp;$1.</li>
<li>Needham analyst Chris Pierce reiterated a Hold rating on Lucid.</li>
<li>Cantor Fitzgerald analyst Andres Sheppard reiterated a Neutral rating on maintained the $3&nbsp;price target.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;</a>
LCID Price Action: At the time of writing, Lucid shares are trading 13.8% lower at $2.25, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

LCID

What's Going On With Lucid Group Stock Wednesday?

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday.
The Dow traded down 0.32% to 43,482.16 while the NASDAQ gained 0.07% to 19,038.99. The S&amp;P 500 also fell, dropping, 0.01% to 5,954.69.
Check This Out: <a href="https://www.benzinga.com/25/02/43952829/top-3-materials-stocks-that-may-keep-you-up-at-night-in-february">Top 3 Materials Stocks That May Keep You Up At Night In February</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Wednesday.
In trading on Wednesday, consumer staples shares fell by 1.5%.
Top Headline
TJX Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) posted better-than-expected fourth-quarter FY25 earnings results.
The company's fourth-quarter FY25 sales remained flat year-on-year to $16.4 billion, beating the analyst consensus estimate of $16.20 billion.
Overall comp store sales increased 5%, well above the Company's plan, and were driven by an increase in customer transactions. Adjusted EPS of $1.23 beat the consensus estimate of $1.16.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares shot up 116% to $2.54 after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.</li>
<li>Shares of Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>)got a boost, surging 59% to $3.72 after the company announced that its Mullen ONE and Mullen THREE vehicles have been added to National Auto Fleet Group&#8217;s Sourcewell contract for public sector government purchasing.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares were also up, gaining 80% to $6.80 after the company reported fourth-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares dropped 40% to $10.67 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) were down 17% to $311.57 with two new short reports adding to the targets against the high-rising stock.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) was down, falling 31% to $1.6250 after the company posted quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $68.79 while gold traded up 0.4% at $2,930.50.
Silver traded up 1.1% to $32.165 on Wednesday, while copper rose 1.2% to $4.5795.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.99%, Germany's DAX 40 gained 1.71% and France's CAC 40 climbed 1.15%. Spain's IBEX 35 Index rose 1.64%, while London's FTSE 100 rose 0.72%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index gaining 1.02% and Hong Kong's Hang Seng Index surging 3.27%.
Economics
<ul>
<li>U.S. mortgage applications declined by 1.2% from the previous week during the week ending Feb. 21</li>
<li>U.S. crude oil inventories declined by 2.332 million barrels in the week ended Feb. 21, compared to market estimates of a 2.54 million gain, the EIA said.</li>
<li>Sales of new single-family homes in the U.S. dipped 10.5% to an annualized rate of 657,000 in January.</li>
<li>Building permits declined by 0.6% to an annualized rate of 1.473 million in January.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

Eurozone

Commodities

ENVB

FLYW

GERN

MULN

PRCH

Dow Dips Over 100 Points; TJX Earnings Top Views

Easily one of the most consequential decisions in recent memory, President Donald Trump reaffirmed earlier this week that his administration will <a href="https://www.benzinga.com/news/global/25/02/43926015/trump-confirms-tariffs-on-canada-mexico-will-take-effect-as-planned">proceed with tariffs on imports</a> from Canada and Mexico. Within this high-level action, the administration also signed an executive order on Tuesday which authorizes an analysis on the national security and economic impact of imports of <a href="https://www.nytimes.com/2025/02/25/us/politics/trump-tariffs-copper.html">copper</a> and other commodities. Subsequently, Southern Copper Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) has been marching higher.
Fundamentally, as the New York Times reported, the investigation will help determine the net viability of tariffs applied on copper. A critical commodity, the manufacturing and construction industries widely use the metal. It's also a critical component for the U.S. military. Perhaps most pertinent to the current ecosystem, copper represents one of the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43432736/copper-stocks-on-shaky-ground-jpmorgan-analysts-say-tariffs-deepseek-cloud-outlook">unsung heroes of artificial intelligence</a>.
While such a notion may sound odd at first blush, a drop in demand for the commodity represented one of the less-discussed anxieties tied to the DeepSeek impact, the Chinese AI model that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43239042/magnificent-seven-broadcom-lose-nearly-900-billion-in-value-as-deepseek-sparks-ai-carnage-why-this-expert-is-still-bullish-on-us-tech">roiled the tech sector</a> in late January. Data centers fuel copper demand so a paradigm shift in machine intelligence could have significant implications for its supply chain.
To be completely transparent, the narrative for SCCO stock isn't completely bullish. For one thing, the copper tariffs may never materialize, which could sink momentum. Second, even if tariffs occur, it's not clear that such an action would be positive. One of the lessons from Trump 1.0 is that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43432736/copper-stocks-on-shaky-ground-jpmorgan-analysts-say-tariffs-deepseek-cloud-outlook">tariffs ultimately hurt copper stocks</a>.
<h2 class="wp-block-heading">Technical and Statistical Backdrop Could Gently Push SCCO Stock Higher</h2>
Although the long-term prospects for SCCO stock remain up in the air, intrepid traders can potentially front run tomorrow's headlines. Effectively, the idea is to leverage the concept colloquially known as <a href="https://www.benzinga.com/markets/equities/24/07/39743338/s-p-500-to-plunge-more-than-20-near-term-top-economist-breaks-down-broader-market-vs-small-cap-d">buy the rumor, sell the news</a>. Enticingly, those tempted to engage this trading idea may have supporting arguments from technical analysis and statistical tendencies.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142736/SCCO-stock-technical-analysis-1024x593.jpg" alt="" class="wp-image-800158" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142736/SCCO-stock-technical-analysis-1024x593.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142736/SCCO-stock-technical-analysis-300x174.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142736/SCCO-stock-technical-analysis-768x444.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142736/SCCO-stock-technical-analysis.jpg 1030w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure>
First, it's possible that SCCO stock is currently charting a pattern reminiscent of a <a href="https://www.benzinga.com/money/stock-chart-patterns">bullish pennant formation</a>. Market technicians will almost certainly argue that the current pattern doesn't meet the criteria of a "classic" pennant. Admittedly, it's not the strongest argument for optimism in Southern Copper. That said, it's intriguing that a formation resembling a pennant has materialized amid a key fundamental development.
Second and more convincing — at least to some traders — is the statistical framework. Using pricing data going back to January 2019, SCCO stock demonstrates an upward bias. A position entered at the beginning of the week has a 52.34% chance of rising by the end of it. Over the next eight weeks, the long odds rise to 57.32%.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142805/SCCO-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-800159" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142805/SCCO-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142805/SCCO-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142805/SCCO-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26142805/SCCO-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
It's also worth noting that these probabilities don't shift materially under dynamic conditions. Specifically, SCCO stock lost 4.4% last week. Historically, though, when SCCO loses up to 5% in a one-week period, bullish probabilities have a tendency of pushing forward relative to the baseline. For instance, in the subsequent week following modest volatility, SCCO's long odds rose to 56.64%, a small but noticeable improvement over 52.34%.
<h2 class="wp-block-heading">Two Possible Approaches To Consider</h2>
By law, the commerce secretary, Howard Lutnick, who will spearhead the aforementioned economic analysis on foreign copper, has 270 days to present a report to the president. However, the New York Times mentioned that Peter Navarro, a senior counselor for trade and manufacturing, stated that Lutnick would move "in Trump time, which is as quickly as possible."
Of course, traders must then speculate as to what that will actually mean. For those who are thinking short term, there are two avenues available.
The first avenue is the riskiest, which involves a <a href="https://www.benzinga.com/money/bull-spread">bull call spread</a> for the options chain expiring March 21. Assuming the positive scenario, the median return over a three-week period will land somewhere in the neighborhood of 5.5% or potentially a bit higher. Based on an estimated price of $94, this projection would translate to an upside target in the neighborhood of $100.
With that in mind, extremely aggressive traders could target the 97.50/100 bull spread. This transaction involves buying the $97.50 March 21 call at an ask of $285 and selling the $100 March 21 call at a bid of $165. The trader uses the proceeds from the short call to partially offset the debit paid for the long call, leading to a net debit of $120. The maximum payout should SCCO reach $100 or above at expiration is $130, or 108.33%.
The other idea, which is still wildly risky, is to consider the 100/105 bull call spread for the options chain expiring April 17 (the Friday of that week is a <a href="https://www.nyse.com/markets/hours-calendars">holiday</a>). Over an eight-week period — assuming the current week as the first — the positive scenario has historically demonstrated a median return of 13.14%, projecting SCCO stock to hit $106.35.
Therefore, it's theoretically reasonable to believe that SCCO has a chance to hit the $105 short strike price target at expiration. However, a lot of things have to go right over the next several weeks.

Options

SCCO

Options Corner: Copper Tariff Fears Spark Pragmatic Trade In Southern Copper

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has been a known commodity among celebrities for years. One of the earliest adopters of XRP fame? <a href="https://www.benzinga.com/topic/snoop-dogg">Snoop Dogg</a>.
What Happened: In May 2018, Snoop Dogg performed at an XRP-themed event, sparking speculation about his involvement with the token. 
The crypto community speculated whether Snoop would endorse XRP, but the rapper made no public statements about holding or promoting the asset. 
Ripple also clarified that he was not paid in XRP for the performance.
This wasn't Snoop Dogg's first interaction with crypto:
<ul>
<li>2013: He tweeted, "My next record available in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) n delivered in a drone."</li>
<li>2021: After Robinhood launched Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) trading, he jokingly <a href="https://x.com/SnoopDogg/status/956633426261524480">said</a>, "Putting tha Crip in Crypto!"</li>
<li>2022: In a July CNBC interview, he <a href="https://www.youtube.com/watch?v=N9UR3VTLbvQ">expressed</a> interest in NFTs and the ownership benefits of digital collectibles and not only become a marketing tool. For the then drawdown in crypto markets, he said that it was just the "weeding" out of all the people that are not supposed to be in the space.</li>
<li>2023: He <a href="https://x.com/SnoopDogg/status/1644350850511556608">showcased</a> a custom golden Ledger Nano X wallet, designed by Eliantte &amp; Co.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43861244/xrp-to-be-part-of-the-crypto-reserve-after-donald-trumps-social-media-post-not-so-fast-pol">XRP To Be Part Of The Crypto Reserve After Donald Trump&#8217;s Social Media Post? Not So Fast, Polymarket Traders Say</a>
<h3 class="wp-block-heading">If You Bought XRP Every Time Snoop Talked Crypto…</h3>
In 2018, when he appeared at the XRP event, prices remained as low as $0.7389. 
When the rapper spoke about crypto in 2021, XRP had already spiked to $1.0969 generating a return of 48%.
In total, XRP has delivered a 193.7% return since 2018. The rally is driven by multiple factors like a potential XRP ETF, rising institutional adoption and Ripple's business development.
What's Next: Crypto chart analyst Ali Martinez noted the TD Sequential indicator flashing a sell signal on the 2-week XRP chart, implying an impending correction. The indicator has reflected high accuracy in XRP prediction since 2022, according to the analyst.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The TD Sequential indicator has been highly accurate in predicting <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> price direction since 2022. It now flashes a sell signal on the 2-weeks chart, suggesting an impending correction. <a href="https://t.co/K4DaBDUihQ">pic.twitter.com/K4DaBDUihQ</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1894726860296356237?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42303487/if-you-invested-1000-in-xrp-token-when-snoop-dogg-performed-at-ripple-community-event-at-consensus-2018-heres-how-much-youd-have-today">If You Invested $1,000 In XRP Token When Snoop Dogg Performed At Ripple Community Event At Consensus 2018, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Did You Know That Snoop Dogg Performed At An XRP Party In 2018? Here's What Happened

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Janssen Biotech has filed a lawsuit against Samsung Bioepis, alleging the company violated a settlement agreement regarding selling a biosimilar version of Stelara, a widely used treatment for autoimmune diseases.
Janssen claims Samsung's actions could unfairly disrupt competition and diminish Stelara's market share.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40316445/medicare-costs-for-johnson-johnsons-psoriasis-drug-stelara-double-when-obtained-at-pharmacies" rel="noreferrer noopener">Medicare Costs For Johnson &amp; Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies</a>
Stelara (ustekinumab) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Janssen had previously reached agreements allowing competitors to introduce biosimilar versions under specific conditions. As part of one such settlement, Samsung was authorized to sell its biosimilar, Pyzchiva, in the U.S. beginning February 22, 2025.
However, Janssen alleges that in December 2024, Samsung disclosed its intent to authorize an additional private-label biosimilar through a third-party company without Janssen's approval, violating their agreement.
Endpoints published a copy of the lawsuit online Tuesday. The lawsuit asserts that this move could allow the third party—a major healthcare conglomerate with a vertically integrated system, including an insurance company, pharmacy chains, and a pharmacy benefits manager—to favor its private label biosimilar over Stelara.
Janssen argues this could lead to an unfair competitive advantage by steering prescriptions away from Stelara and other authorized biosimilars.
Janssen contends that Samsung intentionally concealed aspects of its agreement with the third party, further complicating the situation.
The lawsuit states that despite multiple warnings from Janssen, Samsung failed to justify its actions and refused to offer assurances that it would not proceed with the private label launch.
In August, Johnson &amp; Johnson announced that it would implement significant changes to offering 340B pricing for its popular drugs, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" rel="noreferrer noopener">Stelara and Xarelto</a>.
Price Action: JNJ stock is down 1.75% at $163.19 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43981119/odp-corporation-stock-plunges-over-20-q4-earnings-misses-expectations-as-sales-drop" target="_blank" rel="noreferrer noopener">ODP Corporation Stock Plunges Over 20%: Q4 Earnings Misses Expectations As Sales Drop</a></li>
</ul>
Image By Sundry Photography Via Shutterstock

Biotech

Health Care

Legal

Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug

Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $1.52 in EPS and $3.79 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=VST" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 203.61% over the past year, down 1.1% year-to-date.
Let&#8217;s look at what the charts indicate for Vistra stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/insights/news/25/02/43869170/heres-how-much-you-would-have-made-owning-vistra-stock-in-the-last-5-years">Here&#8217;s How Much You Would Have Made Owning Vistra Stock In The Last 5 Years</a>
<h2 class="wp-block-heading">VST Stock Strongly Bearish Ahead Of Q4 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26125757/Screenshot-2025-02-26-at-11.26.52-PM.png" alt="" class="wp-image-800022" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26125757/Screenshot-2025-02-26-at-11.26.52-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26125757/Screenshot-2025-02-26-at-11.26.52-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Vistra stock, at $146.72, is currently in a strongly bearish trend. The stock is trading below its five-day, 20-day and 50-day exponential moving averages (EMA). 
This signals continued downside pressure. The stock is also experiencing buying interest, which could pave the way for a bullish reversal if momentum strengthens.
The eight-day simple moving average (SMA) at $156.04, 20-day SMA at $163.07 and the 50-day SMA at $158.95 all indicate a bearish setup, suggesting resistance in the near term. 
On the other hand, VST stock remains above its 200-day SMA of $118.27, offering a long-term bullish signal.
Momentum indicators further confirm short-term weakness. The Moving Average Convergence Divergence (MACD) is at a negative 4.08, indicating bearish momentum. 
Meanwhile, the Relative Strength Index (RSI) at 41.43 suggests the stock is approaching oversold conditions. If RSI moves below 30, a potential rebound could materialize, making VST a stock to watch for investors looking for an entry point.
<h3 class="wp-block-heading">Vistra Analysts Consensus Ratings</h3>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/VST/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Vistra stock stands at a Buy currently with a price target of $104.80. 
VST Price Action: Vistra stock was trading at $148.09 at the time of publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/02/43900861/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-54">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Image: Courtesy of Vistra

Technicals

Previews

Tech

Vistra Stock Slumps Below Key Levels As Q4 Earnings Loom: Can Bulls Take Charge?

Last week, the Food and Drug Administration (FDA) said Novo Nordisk A/' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide products, including Wegovy and Ozempic, are no longer in shortage.
Semaglutide injection products were <a target="_blank" href="https://www.fda.gov/media/185526/download?attachment" rel="noreferrer noopener">first</a> added to the FDA's drug shortage list for Wegovy in March 2022 and Ozempic in August 2022.
A lawsuit filed by the compounding groups Outsourcing Facilities Association (OFA) and North American Custom Laboratories, doing business as FarmaKeio Superior Custom Compounding, challenges the FDA's decision to remove semaglutide from the drug shortage list.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43812904/novo-nordisk-sues-singapore-based-kbp-biosciences-over-alleged-data-misrepresentation-in-13-billion-hypertension-drug-deal-seeks-over-800-million-in-damages" rel="noreferrer noopener">Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages</a>
The plaintiffs argue that this action was arbitrary, unlawful, and detrimental to patients who rely on compounded semaglutide for type 2 diabetes, obesity, and cardiovascular disease.
The <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_2f297f7c5f2a45fb89f64fe6a5dcb5c7.pdf" rel="noreferrer noopener">lawsuit</a> highlights that even the manufacturer of FDA-approved semaglutide acknowledged in its earnings release that supply issues and drug <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">shortages were ongoing</a>.
Despite this, the FDA proceeded with its decision without engaging in a formal notice-and-comment rulemaking process, which plaintiffs argue violates the Administrative Procedure Act (APA).
The APA requires federal agencies to provide public notice, solicit input from stakeholders, and offer reasoned explanations for regulatory actions.
In December, Novo Nordisk&nbsp;submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that outsourcing facilities may <a target="_blank" href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" rel="noreferrer noopener">use in drug compounding</a>.
The petition argues that FDA-approved liraglutide-based products, Victoza, Saxenda, and Xultophy, meet patient needs without requiring additional compounded versions, which Novo Nordisk contends pose significant safety and efficacy risks.
Last year, the FDA determined that the Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide injection shortage had been resolved.
The compounding groups <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_956a40069f7c4b768199e187953cd15f.pdf" rel="noreferrer noopener">filed</a> a complaint alleging that removing the drug from the shortage list is based solely on the manufacturer's production capabilities.
In January, Eli Lilly filed a motion to intervene as a defendant in a case against the FDA brought by the Outsourcing Facilities Association and <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">FarmaKeio Custom Compounding</a>.
Price Action: LLY stock is up 1.22% at $912.79 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43980584/united-parks-q4-earnings-miss-estimates-as-unusually-poor-weather-impacts-results" target="_blank" rel="noreferrer noopener">United Parks Q4 Earnings Miss Estimates As ‘Unusually Poor' Weather Impacts Results</a></li>
</ul>
Image via Shutterstock

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision

Citizens Capital Markets analyst Trevor Walsh reiterated the Market Outperform rating on Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), <a href="https://www.benzinga.com/quote/AXON/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $725.</a>
On Tuesday, the company reported fourth-quarter results, with quarterly revenue of&nbsp;$575 million&nbsp;that grew 34% year over year, driven by double-digit growth in each product segment.
Walsh highlighted Axon&#8217;s total addressable market was now $129 billion, up from $77 billion in the first quarter of 2024, which reflected the growth from acquisitions like Fusus and Dedrone.
While current revenues of $2.1 billion were primarily from law enforcement, with only 15% market penetration, significant opportunities remained in real-time operations, drones and robotics, and AI solutions, contributing $20 billion, $20 billion and $17 billion, respectively, to the total addressable market.
Also Read:<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43981217/applovin-stock-drops-on-multiple-short-reports-allegations-of-copying-meta-creating-smoke-and-mirrors-game" rel="noreferrer noopener"> AppLovin Stock Drops On Multiple Short Reports: Allegations Of Copying Meta, Creating &#8216;Smoke And Mirrors Game&#8217;</a>
The analyst acknowledged some skepticism over these high total addressable market estimates but considered Axon&#8217;s strong customer mindshare, product innovation and go-to-market strategy to make this outlook credible.
Per the analyst, Axon&#8217;s international and enterprise opportunities were at an inflection point and expected to contribute significantly in FY25. Management&#8217;s focus on meeting with international clients and the potential of TASER 10 and AI-driven efficiencies are seen as key factors for accelerating foreign contract wins.
The analyst highlighted that Axon met its aggressive $4.0 billion bookings target for 2H24 and saw a significant acceleration in calculated billings to 54%.
The analyst described management&#8217;s guidance as more bullish than previous years, with the pipeline for FY25 looking stronger, which suggested potential upside to guidance as the year progresses.
AXON Price Action: AXON shares are trading higher by 16.63% to $579.26 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/restaurants/25/02/43977975/mcdonalds-says-no-to-egg-surcharges-celebrates-50-years-of-egg-mcmuffin-breakfast-experience-anchored-in-great-value" target="_blank" rel="noreferrer noopener">McDonald&#8217;s Says No To Egg Surcharges, Celebrates 50 Years Of Egg McMuffin: &#8216;Breakfast Experience Anchored In Great Value&#8217;</a></li>
</ul>
Photo: Courtesy Axon

AXON

Axon's $129 Billion Market Opportunity In Focus: Analyst Sees Strong Product Innovation And More

Wall Street analysts rerated ZoomInfo Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) after the company reported its <a target="_blank" href="https://www.benzinga.com/news/management/25/02/43960862/zoominfo-technologies-q4-earnings-revenue-beat-eps-beat-strong-guidance-shares-surge" rel="noreferrer noopener">fourth-quarter results Tuesday</a>.
<ul>
<li>Needham analyst Joshua Reilly reiterated ZoomInfo with a Buy and a <a href="https://www.benzinga.com/quote/ZI/analyst-ratings" target="_blank" rel="noreferrer noopener">$15 price target</a>.</li>
<li>Citizens Capital Markets analyst Patrick Walravens maintained ZoomInfo from Market Perform to Market Perform.</li>
<li>Piper Sandler analyst Brent Bracelin upgraded ZoomInfo from Underweight to Neutral and raised the price target from $10 to $11.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43980437/intuit-sees-ai-driven-growth-with-turbotax-credit-karma-analyst-raises-price-forecast" target="_blank" rel="noreferrer noopener">Intuit Sees AI-Driven Growth With TurboTax, Credit Karma: Analyst Raises Price Forecast</a>
Needham: Reilly noted that ZoomInfo is at an inflection point following GTM and product changes over the last 18 months. This positions the company to tackle their newly defined Up-Market (100+ employees) customer segment, which comprises 70% of ACV exiting the year and likely 75% by the year-end 2025. 
CoPilot is now $150 million in ACV, and Operations OS growth accelerated sequentially by 5 points to 27% with over $100 million now in ACV. Reilly noted management wisely positioned guidance conservatively for 2025 and is increasingly confident they can return to a beat and raise cadence as the year progresses. Given the current valuation, he expects additional multiple expansion post-fourth-quarter results.
Reilly projected first-quarter revenue of $295.5 million and adjusted EPS of $0.22.
Citizens Capital Markets: Walravens rerated after the company reported better-than-expected fourth-quarter 2024 results with adjusted EPS of 26 cents (consensus 22 cents), operating margins of 37.5% (consensus 35.1%), and unlevered free cash flow of $93.6 million (Citizens $71.7 million) on revenue of $309 million (consensus $298 million), down 2% versus down 3% last quarter, cRPO of $850 million (Citizens $836 million), down 1% versus down 2% last quarter all of which left the stock up 15% in the aftermarket after having fallen 9% year to date versus a 1% decrease for the Nasdaq and flat for the Russell 3000.
On the positive side, ZoomInfo seems to be moving in the right direction. The company saw several positive developments in the fourth quarter. This includes an uptick in its $100,000-plus customer cohort, strength in the upmarket, stabilization in the SMB, and its first sequential increase in NRR since first-quarter of 2022 while on a more cautious note.
Walravens projected first-quarter revenue of $295.5 million and adjusted EPS of $0.22.
Piper Sandler: Operational challenges remain elevated despite better-than-feared results. Fourth-quarter revenue declined for the third consecutive quarter.
The tepid first-quarter growth outlook implies revenue could decline 4%- 5%, with operating margin sliding to 33% (versus 37.5% in the fourth quarter). That said, there were promising (albeit early) signs of stabilization after two years of eroding metrics. In-period NRR improved during the fourth quarter, helping to stabilize TTM NRR to 87% (versus 87% one year ago).
Downmarket customers (33% mix) remain a drag on growth. Bracelin, however, is encouraged by the highest number of new enterprise customer adds in two years. The combination of new DaaS products in May, more favorable SMB billing compares starting in April, and the continuation of double-digit enterprise ARR growth could kick-start a potential turnaround. The analyst upgraded, given that the first quarter could mark a fundamental trough in growth and margins.
Bracelin projected first-quarter revenue of $295.6 million and adjusted EPS of 22 cents.
Price Action: ZoomInfo stock is up 24.9% at $11.90 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43973550/photronics-q1-earnings-beats-estimates-strong-ic-demand-growth-in-high-end-products-ceo-cautious-on-2025-outlook" target="_blank" rel="noreferrer noopener">Photronics Q1 Earnings: Beats Estimates, Strong IC And FPD Demand, Growth in High-End Products, CEO Cautious on 2025 Outlook</a></li>
</ul>
Image: Shutterstock

Reiteration

ZoomInfo Sees Stock Surge As Analysts Spot Signs of Turnaround Amid Upmarket Growth

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is poised to release its fourth-quarter earnings today after market close. Analysts project earnings per share of 84 cents and revenues of $38.1 billion. Given Nvidia&#8217;s significant presence in <a href="https://www.benzinga.com/etfs">various ETFs</a>, this earnings report could substantially influence their performance.
ETFs with Nvidia Exposure To Keep An Eye On
Nvidia holds considerable weight in several prominent ETFs, notably:
VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>): Approximately 19% of this ETF&#8217;s holdings are in Nvidia, making it highly sensitive to Nvidia&#8217;s stock movements.
SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>): Nvidia comprises about 6.14% of this fund, reflecting its status as one of the largest companies in the S&amp;P 500 Index.
Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>): With an 8.1% allocation to Nvidia, this ETF is influenced by the company&#8217;s performance, given its focus on major non-financial companies listed on the Nasdaq.
Also Read: <a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43972061/nvidia-stock-stumbles-into-q4-earnings-can-it-defy-nvda-bears">Nvidia Stock Stumbles Into Q4 Earnings: Can It Defy NVDA Bears?</a>
History and Relevance Of Nvidia As An Important Stock
For a quick memory refresh, in January, Nvidia experienced a significant stock decline of over 20% within days, primarily due to <a href="https://in.benzinga.com/tech/25/01/43302711/nvidia-hardest-hit-among-mag-7-stocks-by-deepseek-and-this-stock-ranked-second">concerns about China&#8217;s DeepSeek AI model</a> potentially reducing demand for Nvidia&#8217;s AI chips. Despite this sharp drop, the SPDR S&amp;P 500 ETF Trust, where Nvidia holds a 6.5% weighting, saw a minimal decrease of less than 2% from its all-time highs, indicating the broader market&#8217;s resilience.
Although Nvidia is no longer the largest company by market capitalization, Apple having reclaimed the top spot, it remains a substantial component of major ETFs like SPY. Nvidia&#8217;s performance influences not only its stock but also the semiconductor industry and tech giants that rely on its products, creating ripple effects throughout the market.
As Nvidia prepares to report its fourth-quarter earnings after the market closes today, analysts anticipate strong results, though uncertainties persist regarding the extent of outperformance. Previous earnings reports have led to mixed stock reactions, with notable fluctuations following each announcement. For instance, the stock rose more than 9% in response to its Q1 2024 results.
Investors are keenly observing whether Nvidia can surpass expectations amid concerns about slowing growth, margin pressures, and the impact of AI developments like DeepSeek. Nonetheless, while Nvidia&#8217;s influence on the broader market has slightly diminished, its earnings report remains a critical event for investors, with potential implications for related sectors and the overall market sentiment.
Also Read: <a href="https://www.benzinga.com/25/02/43948627/nvidia-stock-quite-cheap-ahead-of-q4-earnings-analyst-says-growth-story-is-intact">Nvidia Stock &#8216;Quite Cheap&#8217; Ahead Of Q4 Earnings: Analyst Says &#8216;Growth Story Is Intact&#8217;</a>
Experts Weigh In Ahead Of The Earnings
Nvidia stock maintains a <a href="https://www.benzinga.com/quote/nvda/analyst-ratings">consensus analyst rating</a> of Buy, with an average price target of $172.28.
Recent evaluations from Rosenblatt, Morgan Stanley, and Tigress Financial suggest a potential upside of over 50%, with an average price target of $197.33.
Analysts from Wedbush and Oppenheimer have <a href="https://www.investopedia.com/what-analysts-think-of-nvidia-stock-ahead-of-earnings-preview-q4-fy2025-update-11683525">reaffirmed </a>their price targets at $175, citing increased demand for Nvidia&#8217;s advanced chips as major technology companies expand their investments in AI infrastructure. UBS analysts, maintaining a $185 price target, observe that rising investor expectations and improvements in the supply chain could boost sales of Nvidia&#8217;s Blackwell line.
Oppenheimer analysts also note that the rapid emergence of Chinese AI startup DeepSeek may positively impact Nvidia, as increased competition encourages American clients to intensify their AI development efforts.
Investors express concerns about potential spending reductions by Nvidia&#8217;s key customers, especially following significant capital expenditures in prior years and recent AI advancements emerging from China, according to a CNBC <a href="https://www.cnbc.com/2025/02/25/nvida-to-report-earnings-amid-infrastructure-spending-deepseek-concerns.html">report</a>.
A significant portion of Nvidia&#8217;s revenue is derived from a select group of companies constructing extensive server infrastructures, commonly referred to as &#8220;hyperscalers.&#8221; In fiscal 2024, Nvidia reported that a single customer accounted for 19% of its total revenue. Consequently, any indication of reduced spending by these major clients could significantly influence Nvidia&#8217;s stock performance.
Investors are concerned that growth may be slowing, and margins could be under pressure, according to etf.com. A strong earnings report from Nvidia could lead to an uptick in ETFs&#8217; values, while disappointing results might exert downward pressure on them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/43979861/mortgage-rates-hit-2025-lows-3-mbs-etfs-to-consider">Mortgage Rates Hit 2025 Lows: 3 MBS ETFs To Consider</a></li>
</ul>
Photo: Shutterstock

NVDA

How Nvidia's Q4 Earnings Could Impact Major ETFs

Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock is trading higher on Wednesday ahead of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&#8217;s earnings report, which is scheduled to be released today after <a href="https://www.benzinga.com//node/43981913">the market closes.</a>
The Details: Nvidia is set to report its 2025 fiscal-year fourth-quarter earnings, with analysts estimating earnings per share of 84 cents and revenue of $38.05 billion.
In its 2025 fiscal-year third-quarter earnings report, the company guided revenue of $37.5 billion, plus or minus 2%, for the fourth-quarter. Nvidia also guided non-GAAP operating expenses of $3.4 billion and a gross margin of 73.5%.
Palantir shares may be trading higher in anticipation of Nvidia&#8217;s earnings report as both companies are heavily involved in artificial intelligence (AI) and Nvidia&#8217;s earnings may be seen as a barometer for AI sector performance. In addition, positive results from Nvidia could generate broader market optimism, especially for other AI and technology companies.
What Else: AI stocks may be rising following Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) <a href="https://www.benzinga.com//node/43981913">filing</a> its earnings reports for the 2024 fiscal-year and the first and second quarters of the 2025 fiscal-year. This comes after Ernst &amp; Young resigned as the company&#8217;s financial auditor due to internal control issues, and SMCI hired BDO as its new auditor.
The company has now regained compliance with the NASDAQ listing requirements. This could signal stability and growth potential to investors, which may be lifting sentiment and driving AI sector stock prices higher.
&#8220;With our financial reporting now current, we can now fully focus on executing our proven winning growth strategy through technology, product and solution innovations, time-to-market advantage, global footprint, and green computing. We are investing extensively in people and processes across our engineering, sales, finance, accounting, compliance, and operations to achieve our great mission in DLC, Data Center Building Block Solution (Supermicro 4.0) as well as our revenue target,&#8221; said Charles Liang, President and CEO of SMCI.
See Also: <a href="https://www.benzinga.com/25/02/43981679/top-3-real-estate-stocks-that-may-fall-off-a-cliff-in-q1">Top 3 Real Estate Stocks That May Fall Off A Cliff In Q1</a>
PLTR Price Action: At the time of writing, Palantir shares are trading 1.20% higher at $88.87, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

PLTR

SMCI

What's Going On With Palantir Stock Wednesday?

Government Trades

Associated Banc-Corp

top performing ASB trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga